The Association of American Cancer Institutes (AACI) congratulates Monica Bertagnolli, MD, on her United States Senate confirmation as the next director of the National Institutes of Health (NIH). As an association representing over 100 leading academic cancer centers in the U.S. and Canada, AACI enjoys a longstanding relationship with the NIH and the National Cancer Institute (NCI).

With more than three decades of experience as a cancer surgeon, physician, researcher, and leader, Dr. Bertagnolli brings a wealth of knowledge to the role of NIH director. From clinical trials and precision medicine—two areas of intense focus for NIH—to the Biden Cancer Moonshot and federal programs mapping the contours of cancer research, Dr. Bertagnolli has a deep understanding of the value of scientific discovery that AACI believes will help guide her work.

“In her role as director of the NCI, Dr. Bertagnolli established a cancer plan for the U.S., which highlighted the need to reach beyond existing partnerships to meet our goals,” said AACI President Robert A. Winn, MD, director of VCU Massey Comprehensive Cancer Center. “AACI is grateful for her commitment to working together to prevent, detect, and treat cancer, and to eliminate disparities in cancer research and care. We are excited about Dr. Bertagnolli’s vision for the NIH and believe her expertise and passion for scientific discovery will serve her well.”

AACI Executive Director Jennifer W. Pegher added, “AACI thanks Dr. Bertagnolli for her service since October 2022 as the first woman director of the NCI. We look forward to continued collaboration with Dr. Bertagnolli in her new role to advance our shared goals of accelerating scientific progress and promoting health equity.”